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This study aimed to compare the biochemical composition of saliva from patients
with eating disorders (EDs) with saliva from control subjects with no ED. All
patients who initiated outpatient treatment in an ED clinic during a 12-month per-
iod were invited to participate. Of the 65 patients who started treatment during the
period, 54 (50 female patients/four male patients; mean age: 21.5 yr) agreed to par-
ticipate. The controls were 54 sex- and age-matched patients from a dental health
clinic. All participants completed a questionnaire and underwent dental clinical
examinations, including laboratory analyses of saliva. The proportion of subjects
with unstimulated salivary hyposalivation was lower in the ED group and not corre-
lated with intake of xerogenic drugs. Signiﬁcant diﬀerences in the biochemical com-
position of saliva were found almost exclusively in the unstimulated state, with
albumin, inorganic phosphate, aspartate aminotransferase (ASAT), chloride, magne-
sium, and total protein all being signiﬁcantly higher in the ED group. Conditional
logistic regression showed that higher ASAT and total protein concentrations were
relatively good predictors of ED, with sensitivity and speciﬁcity of 65% and 67%,
respectively. In conclusion, elevated salivary concentrations of ASAT and total pro-
tein may serve as indicators of ED as well as of disease severity. Future studies are
needed to corroborate these initial ﬁndings.
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Eating disorders (ED) are psychosomatic disorders that
may inﬂuence oral health because dental hard tissue, as
well as salivary conditions, may be aﬀected. In this
regard, increased prevalences of dental erosion and
caries have been reported, in addition to xerostomia,
hyposalivation, and enlargement of salivary glands (1–8).
Eating disorders are characterized by a speciﬁc psy-
chopathology focused on eating behavior, body weight,
and shape, and the individual’s eﬀorts at controlling
them (9). In the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) (10), which is
used in the present study, the EDs are divided into
three main diagnoses: anorexia nervosa (AN), bulimia
nervosa (BN), and ED not otherwise speciﬁed (ED-
NOS). Anorexia nervosa is mainly characterized by
food restriction leading to underweight, and BN by
binge eating and inappropriate behaviors to compen-
sate for the binge eating (e.g. self-induced vomiting, use
of laxatives/diuretics, and excessive exercise). Eating
disorders not otherwise speciﬁed is a very heteroge-
neous category, comprising inter alia AN-like and BN-
like atypical EDs, as well as a preliminary diagnosis
called binge eating disorder (10, 11). There is frequently
an overlap in symptoms and behavior among the ED
diagnoses. Self-induced vomiting can, for example, be
found in almost all patients with EDs, irrespective of
diagnosis. Diagnostic shifts over the course of the ED
is common, as are repeated relapses after healthy peri-
ods (12).
There are well-established connections between EDs
in general, their behavioral speciﬁers (e.g. binge eating
and vomiting), and oral complications. The connection
is especially apparent between bulimic behaviors and
dental erosion, but is also present with salivary and
other oral-related factors (3, 7, 8, 13–16). In addition,
the duration of the ED may have a signiﬁcant impact
on these factors (8).
Eating disorders are likely to aﬀect oral health and
the saliva in diﬀerent ways, depending on the expres-
sion, intensity, and duration of the ED symptoms. It
may therefore be of interest to study salivary factors –
both the quantity and the composition – and analyze
the results in terms of duration of the disease and beha-
vioral symptoms, such as vomiting or binge eating.
The aim of the study was therefore to investigate the
biochemical composition of saliva from patients with
EDs and in the diﬀerent ED subgroups, and to com-
pare it with that of saliva from sex- and age-matched
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healthy controls. It is hypothesized that the composi-
tion of saliva from patients with EDs may be aﬀected
and that speciﬁc markers for ED disease may exist.
Material and methods
Participant selection and inclusion/exclusion criteria
During a 12-month period, a total of 65 patients accepted
and initiated psychiatric/medical outpatient treatment for
EDs at the Eating Disorder Clinic, €Orebro County Coun-
cil, €Orebro, Sweden. The ED diagnoses were made by the
expert team at the clinic. All 65 patients were invited to
participate in this study and, of these, 54 (83%) agreed to
participate at their ﬁrst physical examination. A control
group of 54 subjects, matched for sex and age, was
selected from the standard recall patients at a Public Den-
tal Health Clinic, €Orebro, Sweden. The selection was made
from the consecutive list of patients who were to be given
an appointment for a routine check-up. The matching of
controls was based on gender and date of birth. The sex-
and age-matched controls were examined during February
to June 2006.
In order to identify and exclude, from the controls,
patients with risk for having an ED, each potential control
subject was assessed using the Symptom Index of the Eat-
ing Disorder Inventory-2 (EDI-2) (17). The EDI-2 is a 91-
item questionnaire that is widely used in the study of EDs
and is divided into 11 subscales, three of which are sub-
scales of central symptoms (the symptom index, i.e.
includes the subscales drive for thinness, bulimia, and
body dissatisfaction). In the present study, only the symp-
tom index was used, which includes 23 of the 91 items in
the questionnaire. Among the 54 controls ﬁrst selected,
two subjects with risk for EDs (i.e. a score of >14, accord-
ing to the EDI-2 symptom index) were found. These sub-
jects were excluded from the control group and two
additional controls were selected, evaluated using the EDI-
2, and found to be suitable for inclusion.
Of the 11 patients who declined to participate in the
study (x = 20.5 yr, range 14–38 yr, all women), four were
diagnosed with AN and seven were diagnosed with ED-
NOS. The reasons given for not participating were: did
not consider herself to have any dental problem (one
patient), failed to attend the appointment (one patient),
did not have the time (three patients), and was not com-
fortable with participation (e.g. long travel time and did
not like to answer questions, etc.) (six patients). There was
no statistically signiﬁcant diﬀerence regarding age, gender,
and ED diagnoses between the non-participants and the
study group.
The study was approved by the Ethics Committee of
the €Orebro region, Sweden, and informed consent was
obtained from all participants. In the case of children,
parental consent was also obtained. As an incentive to
participate in the study, all control subjects were oﬀered
cinema tickets (children) or a free ordinary recall (adults).
Questionnaire and clinical examination
A questionnaire was constructed in collaboration with the
staﬀ at the ED clinic. It comprised 196 questions on soci-
odemographic factors, general and oral health, and life-
style. The questionnaire was given to participants of both
study and control groups, except for 20 questions that
were speciﬁcally related to the ED and were therefore not
given to the controls. All medication intake was recorded
and its possible xerogenic eﬀect was classiﬁed according to
1177 VARDGUIDEN’S (18) list of drugs that are known to
cause mouth dryness. The clinical examination of the
study group was performed at the specialist clinic for ED
in an ordinary medical examination room using mobile
dental equipment and an operating light. The controls
were examined using the operating light from the same
mobile equipment but in the dental clinic. The status of
the salivary glands was assessed by visual examination and
palpation. The examiner was blinded to the medical his-
tory and to the results of the questionnaires for both ED
patients and controls. Full details of the questionnaire,
clinical examination, and the results of oral health status
and symptoms related to oral health and temporomandib-
ular disorders (TMDs) in this sample have previously been
published (8, 19).
Salivary analyses
The patients were instructed to refrain from eating and
drinking, as well as from oral hygiene and smoking, for
1 h before the appointment. At the appointment, unstimu-
lated whole saliva and paraﬃn-stimulated whole saliva
were collected in precooled tubes on ice, for periods of
15 min and 5 min, respectively. After determining the
secretion rate (ml/min), a small aliquot from the sample of
stimulated whole saliva was used to determine buﬀer
capacity (Dentobuﬀ; Orion Diagnostica, Espoo, Finland).
The remainder of the collected saliva was transported in
dry ice to a freezer and was stored at 80°C until required
for further analyses.
Analyses of the biochemical composition of both
unstimulated and stimulated saliva were carried out at Sahl-
grenska University Hospital, G€oteborg, Sweden. A BM/
Hitachi 917 instrument (Boehringer Mannheim, Indianap-
olis, IN, USA) was used to analyze calcium (mmol/l),
inorganic phosphate (mmol/l), a-amylase (lkat/l), lactate
dehydrogenase (LDH, lkat/l), aspartate aminotransferase
(ASAT, lkat/l), magnesium (mmol/l), creatinine (lmol/l),
and urea (mmol/l) using photometric assays. Total protein
concentration (g/l) was analyzed using turbidity measure-
ments. An ion-selective electrode was used for determina-
tion of potassium (mmol/l), chloride (mmol/l), and sodium
(mmol/l). Nephelometry (IMMAGE 800 Immunochemis-
try System; Beckman Coulter, Brea, CA, USA; or Nephe-
lometer II, Dade Behring, Deerﬁeld, IL, USA) was used
for analyses of albumin (mg/l). The number of moles of
solute that contribute to the osmotic pressure of a solution
– osmoles (mOsm/kg) – was measured by freezing point
depression (Fiske 2400 Multi Sample Osmometer; Nor-
wood, MA, USA).
Statistical methods
Diﬀerences between patients with ED and controls were
calculated using the Wilcoxon signed-rank test (SPSS ver-
sion 20.0; Statistical Package for the Social Sciences, IBM
SPSS, Armonk, NY, USA). In addition to comparing the
ED group with its matched control, comparisons were also
made between subgroups of patients with EDs and their
respective controls. The subgroups comprised: (i) duration
of ED of ≤1 yr or >1 yr; and (ii) present self-induced vom-
iting and/or binge eating behavior or not. P-values of
<0.05 were considered statistically signiﬁcant. Conditional
Eating disorders and salivary factors 159
logistic regression, using the nomreg and the Cox proce-
dures, in SPSS was used to test for statistically signiﬁcant
diﬀerences in salivary variables between ED patients and
controls in unstimulated saliva. Associations within the
ED and control groups were tested using the Pearson cor-
relation coeﬃcient. For variables signiﬁcant in the regres-
sion analysis, a receiver–operating characteristic (ROC)
curve was plotted and the area under the curve (AUC)
was calculated.
Results
Distribution of ED diagnoses and body mass index
The mean age SD for both patients and controls
was 21.5  6.8 yr (range: 10–50 yr; 100 female sub-
jects and eight male subjects). The distribution of ED
diagnoses among the patients was: AN, 28% (14/54
patients); BN, 14% (eight of 54 patients); and ED-
NOS, 58% (32/54 patients). The mean age at onset of
EDs in the study group was 16 (SD 3.8, range: 9–26)
yr, and the mean duration of the disease was 4.5 (SD
6.1, range: 0.3–35) yr. Sixty-one per cent of patients
had had an ED for more than 1 yr. The mean body
mass index (BMI) of subjects in the ED group was
19  4.2 (range: 12–36) and in the controls was
23  4.7 (range: 18–44) (P = 0.001). A more detailed
analysis of oral health status and symptoms related
to TMDs in this sample has previously been reported
(8, 19).
Questionnaire
In the ED group, 34 patients (ﬁve with AN, eight with
BN, and 21 with EDNOS) reported present vomiting
or binge eating, whereas 20 (nine with AN and 11 with
EDNOS) did not. Seventeen per cent of patients with
EDs reported daily xerostomia compared with 6% of
control subjects, whereas xerostomia once a month or
more was reported by 52% and 30% of patients with
ED and control subjects, respectively (P = 0.004).
Swelling in front of the ear (parotid enlargement) was
only reported in the ED group (four patients). Stomach
problems were reported by 59% of patients with EDs
(four with AN, ﬁve with BN, and 23 with EDNOS)
and by 28% of the controls (P = 0.002). The frequency
of intake of xerogenic medications was not signiﬁcantly
diﬀerent between patients with ED and controls. This
was true for both psychotropic (nine patients with ED
and three controls, respectively) and anti-allergic (nine
patients with ED and 11 controls) drugs taken sepa-
rately, as well as in combination (18 patients with ED
and 13 controls).
Clinical findings and salivary analyses
Parotid gland enlargement was found in 31% (n = 17)
of patients with EDs (one with AN, four with BN, and
12 with EDNOS) (P = 0.001) but in none of the con-
trols. The unstimulated salivary secretion rate was
lower in patients with EDs (x = 0.22 ml/min,
SD = 0.19) compared with controls (x = 0.27 ml/min,
SD = 0.21), but not signiﬁcantly so (P = 0.148). During
stimulation, no clinical or signiﬁcant diﬀerences were
found between the study groups (ED group: x =
0.64 ml/min, SD = 0.88; control group: x = 0.66 ml/min,
SD = 0.90). The proportion of subjects with unstimu-
lated hyposalivation (a secretion rate of ≤0.1 ml/min)
was signiﬁcantly higher in the ED group compared
with the control group (39% vs. 21%, respectively;
P = 0.025). Buﬀering capacity did not diﬀer signiﬁ-
cantly between the ED and control groups, and salivary
secretion rate and buﬀering capacity did not diﬀer sig-
niﬁcantly between ED subgroups and controls. Intake
of xerogenic drugs and unstimulated and stimulated
salivary ﬂow showed no signiﬁcant correlation within
the ED group. Among the controls, a tendency for sig-
niﬁcant correlation was found between lower unstimu-
lated saliva secretion rate and intake of psychotropic
and anti-allergic drugs (Pearson R = 0.27; P = 0.05)
but not for each drug taken separately.
The biochemical compositions of unstimulated and
stimulated saliva in the ED and control groups are
shown in Tables 1 and 2. Signiﬁcant diﬀerences were
found almost exclusively for the unstimulated state, in
which albumin, phosphate (Table 1), ASAT, chloride,
magnesium, and total protein (Table 2) were all signiﬁ-
cantly higher among patients with EDs (P = 0.042 to
P = 0.003). In stimulated saliva, only LDH was signiﬁ-
cantly diﬀerent, being higher in the ED group
(P = 0.043) (Table 2). There was a signiﬁcant, negative
correlation between BMI and ASAT in the ED group
(Pearson R = 0.42, P = 0.006), but no such correla-
tion was found among the controls.
Symptoms and signs as a function of duration of
disease and behavior
Unstimulated and stimulated salivary secretion rates
and buﬀer capacity were not signiﬁcantly diﬀerent with
respect to ED subgroups (i.e. duration of disease and
vomiting and/or binge eating behavior or not) com-
pared with matched controls. Moreover, there was no
diﬀerence between frequencies of intake of xerogenic
drugs in ED subgroups. The signiﬁcant diﬀerences
found in biochemical composition relating to duration
of ED and behaviors are shown in Table 3, and all
numerical values for the salivary composition of sub-
groups compared with those of matched controls are
given in Tables S1–S8. A pattern emerged in which
most diﬀerences compared with controls were found in
those in the ED group who had had a duration of dis-
ease of >1 yr (six with AN, seven with BN, and 20 with
EDNOS) and in the group not reporting vomiting and/
or binge eating (nine with AN and 11 with EDNOS).
Furthermore, these diﬀerences were almost exclusively
in unstimulated saliva, with signiﬁcantly higher ion
concentrations compared with matched controls. In
stimulated saliva, only LDH diﬀered signiﬁcantly, in
the subgroup with a duration of the disease of >1 yr.
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Table 1
Biochemical composition of unstimulated and stimulated whole saliva in patients with an eating disorder (ED) compared with that in
sex- and age-matched controls*
Saliva variable
Study group
P
ED Control
n Mean  SD Range n Mean  SD Range
Unstimulated saliva
a-Amylase (lkat/l) 48 1385  917 7–4334 51 1277  1142 14–5612 0.85
Albumin (mg/l) 44 72  81 12–460 47 49  48 6–249 0.003
Calcium (mmol/l) 48 0.82  0.21 0.46–1.28 51 0.76  0.17 0.47–1.23 0.25
Osmoles (mOsm/kg) 46 62  16 33–115 51 56  14 32–90 0.07
Phosphate (inorganic) (mmol/l) 48 6.4  2.2 2.8–13.7 51 5.5  1.8 2.9–10.8 0.04
Potassium (mmol/l) 48 22.3  4.6 14.8–36.9 51 21.0  4.7 13.4–30.7 0.37
Urea (mmol/l) 48 5.15  1.93 0.90–10.20 51 4.68  1.53 2.30–9.80 0.79
Stimulated saliva
a-Amylase (lkat/l) 52 2181  1359 57–6078 53 2400  2154 77–11330 0.73
Albumin (mg/l) 52 52  43 12–236 52 61  57 7–278 0.24
Calcium (mmol/l) 52 0.75  0.18 0.42–1.20 53 0.76  0.14 0.49–1.02 0.86
Osmoles (mOsm/kg) 52 76  18 52–119 53 72  16 50–113 0.20
Phosphate (inorganic) (mmol/l) 52 4.1  1.1 2.4–7.9 53 3.8  0.8 2.2–5.6 0.33
Potassium (mmol/l) 52 20.2  3.2 12.8–30.1 53 20.2  3.0 15.4–27.0 0.76
Urea (mmol/l) 52 3.46  1.20 0.90–7.30 53 3.42  0.97 1.40–6.20 0.79
Descriptive statistics: Mean salivary variables of numerical variables (Wilcoxon signed-rank test).
*P-value in bold indicate a statistically signiﬁcant diﬀerence.
Table 2
Biochemical composition of unstimulated and stimulated whole saliva from patients with an eating disorder (ED) compared with that
in sex- and age-matched controls*
Salivary variable
Unstimulated
P
Stimulated
P
ED Controls ED Controls
n % n % n % n %
ASAT (lkat/l)
<0.10 19 39.6 31 62.0 0.004 1 1.9 0 0 0.66
0.10–0.60 26 54.2 19 38.0 38 73.1 43 81.1
>0.60 3 6.3 0 0.0 13 25.0 10 18.9
Chloride (mmol/l)
<15 3 7.0 12 24.5 0.03 2 3.8 4 7.7 0.52
15–27 36 83.7 37 75.5 41 78.8 42 80.8
>27 4 9.3 0 0.0 9 17.3 6 11.5
Creatinine (lmol/l)
<3 11 22.9 23 45.1 0.09 27 51.9 20 37.7 0.23
3–5 26 54.2 19 37.3 22 42.3 30 56.6
>5 11 22.9 9 17.6 3 5.8 3 5.7
LDH (lkat/l)
<0.2 28 58.3 36 70.6 0.13 24 46.2 31 58.5 0.04
0.2 12 25.0 11 21.6 12 23.1 15 28.3
>0.2 8 16.7 4 7.8 16 30.8 7 13.2
Mg (mmol/l)
<0.1 3 6.3 12 23.5 0.005 31 59.6 29 54.7 0.70
0.10–0.16 21 43.8 25 49.0 18 34.6 22 41.5
>0.16 24 50.0 14 27.5 3 5.8 2 3.8
Protein (total) (g/l)
<0.2 4 9.3 12 24.5 0.016 9 17.3 8 15.4 0.98
0.2–0.5 27 62.8 34 69.4 32 61.5 33 63.5
>0.5 12 27.9 3 6.1 11 21.2 11 21.2
Sodium (mmol/l)
<10 42 87.5 45 88.2 0.50 14 26.9 21 39.6 0.76
10–15 3 6.3 5 9.8 10 19.2 12 22.6
>15 3 6.3 1 2.0 28 53.8 20 37.7
Categorical variables (Wilcoxon signed-rank test).
ASAT, aspartate aminotransferase; LDH, lactate dehydrogenase.
*P-value in bold indicate a statistically signiﬁcant diﬀerence.
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Albumin, ASAT, chloride, magnesium, phosphate,
and protein from unstimulated saliva were signiﬁcantly
diﬀerent according to the bivariate analysis (Tables 1
and 2), and they were entered into the conditional
logistic regression. The ﬁnal model constituted two
variables: ASAT (OR = 3.5) and protein (total;
OR = 2.5). The sensitivity and speciﬁcity for correct
classiﬁcation into the ED group and the control group
were 65.1% and 67.3% for ASAT and protein, respec-
tively, and Nagelkerke R2 = 0.32 (Table 4).
The AUC based on the ROC curve (Fig. 1) was 0.73
(95% CI: 0.62–0.84) for ASAT alone, and 0.75 (95%
CI: 0.65–0.86) for protein alone. With both variables in
the model, the AUC was 0.83 (95% CI: 0.74–0.92).
Including all variables in the model gave an AUC of
0.87 (95% CI: 0.78–0.95).
Discussion
Of the total of 65 patients who accepted and initiated
psychiatric/medical outpatient treatment for ED at the
Eating Disorder Clinic, 54 agreed to participate in the
study. This constitutes a participation rate of 83%,
which is acceptable considering that this is a ‘diﬃcult’
patient group in terms of management and because of
the serious nature of the disease. There were no statisti-
cally signiﬁcant diﬀerences in age, gender, and ED
diagnoses between participating and non-participating
patients. It is therefore probable that the group exam-
ined is largely representative of patients with EDs
referred to an outpatient ED clinic in Sweden. The dis-
tributions of the ED diagnoses and BMI are largely in
agreement with the normal distribution among patients
for ongoing ED treatment, although there was a
slight over-representation of AN and EDNOS and an
under-representation of BN. The sex- and age-matched
controls from the public dental health clinic were con-
sidered to represent a healthy group of individuals.
Table 3
Differences in unstimulated (UWS) and stimulated (SWS) salivary composition in relation to the duration of disease and present
vomiting and/or binge eating (VOM/BE or not (N-VOM/BE)
Salivary variable
ED ≤1 yr (n = 21) ED >1 yr (n = 33) VOM/BE (n = 34)
N-VOM/BE
(n = 20)
UWS SWS UWS SWS UWS SWS UWS SWS
a-Amylase 0.65 0.46 0.91 0.75 0.97 0.70 0.72 0.90
ASAT 0.07 0.48 0.02↑ 0.25 0.09 0.37 0.01↑ 0.74
Albumin 0.24 0.38 0.005↑ 0.47 0.12 0.70 0.004↑ 0.14
Calcium 0.91 0.26 0.12 0.59 0.87 0.27 0.04↑ 0.26
Chloride 0.13 0.37 0.13 0.06 0.13 0.76 0.13 0.21
Creatinine 0.92 0.44 0.03↑ 0.35 0.30 0.66 0.17 0.17
LDH 0.05 0.01↑ 0.57 0.72 0.40 0.12 0.18 0.19
Mg 0.12 0.80 0.02↑ 0.78 0.15 0.37 0.008↑ 0.89
Osmoles 0.30 0.39 0.16 0.01↑ 0.81 0.44 0.01↑ 0.27
Phosphate (inorganic) 0.30 0.44 0.06 0.59 0.39 0.21 0.03↑ 0.94
Potassium 0.56 0.66 0.45 0.43 0.76 0.96 0.04↑ 0.57
Protein (total) 0.31 0.56 0.02↑ 0.69 0.13 0.86 0.04↑ 0.80
Sodium 0.79 0.34 0.53 0.01↑ 1.0 0.48 0.45 0.19
Urea 0.47 0.59 0.21 0.89 0.77 0.94 0.07 0.57
P-values indicate signiﬁcant diﬀerences with respect to matched controls. Arrows indicate a higher (↑) mean/categorical P-value compared
with matched controls.
ASAT, aspartate aminotransferase; ED, eating disorder; LDH, lactate dehydrogenase.
Table 4
Conditional logistic regression (stepwise forward entry method)
with eating disorder (ED) and matched control as the
dependent variable and six independent variables [unstimulated
saliva albumin (mg/l), aspartate aminotransferase (ASAT)
(lkat/l), chloride, (mmol/l), magnesium (mmol/l), phosphate
(inorganic) (mmol/l), and protein (total; g/l)]
B P OR 95% CI for OR
ASAT 1.2 0.044 3.5 1.03–11.5
Protein (total) 0.9 0.038 2.5 1.05–5.9
Nagelkerke R2 = 0.32.
B, regression coeﬃcient; P, signiﬁcance level.
Fig. 1. Receiver–operating characteristic (ROC) curve for
signiﬁcant variables in the regression analysis. The area under
the curve (AUC) was 0.73 for aspartate aminotransferase
(ASAT), 0.75 for protein, and 0.83 for combined
ASAT + protein.
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Even though studies of EDs are often related to their
speciﬁc sub-diagnoses, we decided to study EDs mainly
in relation to their duration and behavioral factors
because the diﬀerent sub-diagnoses frequently overlap
during the course of the disease.
The concentrations of saliva constituents were gener-
ally higher in patients with EDs than in controls, and
those variables that showed signiﬁcant diﬀerences were
almost exclusively found in unstimulated saliva. This
applied both to the total group as well as to the sub-
groups. It is diﬃcult to explain these diﬀerences fully
but a few comments can be made. The patients with
EDs reported, and presented clinically with, enlarge-
ment in the area of the parotid glands signiﬁcantly
more frequently than did controls, and this is in agree-
ment with previous studies (20–22). In the present
study, a great proportion of patients with EDs reported
self-induced vomiting or binge eating. Although the eti-
ology of parotid enlargement in patients with EDs is
not yet clariﬁed, it is believed to be associated with
vomiting and binge-eating behavior (23, 24), even
though an absence of salivary gland hypertrophy can-
not exclude the presence of vomiting behavior (25).
Parotid enlargement has been noted in a variety of con-
ditions besides eating disorders, including alcoholism,
malnutrition, diabetes, cirrhosis, hypothyroidism, obes-
ity, and pregnancy. The eﬀect may also be related to
the amount of saliva secreted, mechanical factors,
inﬂammatory changes, and centrally induced mecha-
nisms (24, 26). Patients with EDs generally experience
xerostomia and hyposalivation, which are considered to
be related to the intake of xerogenic drugs, at least in
BN (7). In this study, no signiﬁcant diﬀerences between
patients with EDs and controls were found regarding
intake of xerogenic medication, and similar results were
found in the subgroups related to duration of the dis-
ease and presence of vomiting/binge eating. Salivary
secretion rates were not signiﬁcantly correlated with
intake of xerogenic drugs in the ED group but were so
in the controls. From the ﬁndings of this study, it can
therefore be concluded that impaired salivary secretion
in patients with EDs is not a function of xerogenic
medication only. In this regard, other factors, such as
the practise of purging behaviors (e.g. combinations of
self-induced vomiting, misuse of laxatives, diuretics,
etc.) and/or excessive exercise, resulting in body dehy-
dration, may contribute to the manifestations of xero-
stomia and hyposalivation observed in patients with
EDs (24). Consequently, the signiﬁcantly altered bio-
chemical composition of saliva in patients with EDs
compared with healthy controls, observed in this study,
must be seen in the light of the aforementioned inﬂu-
ences and may be a direct eﬀect of impaired salivary
function and/or an indirect expression of the ED itself.
Compared with their matched healthy controls, sub-
groups of patients with EDs [i.e. those with a longer
duration of the disease together with those who did not
present with vomiting/binge eating (anorexic behavior)],
diﬀered signiﬁcantly in salivary composition compared
with those with a shorter duration and vomiting/binge
eating behavior (bulimic behavior). It is possible that
the diﬀerence in salivary ﬂow and composition could
be attributed to the eﬀect of longer disease activity and
anorexic behavior, which is likely to have a more severe
impact on bodily physiologic functions. That the diﬀer-
ences between the subgroups and controls is only
caused by hyposalivation (i.e. a higher proportion of
subjects with an unstimulated salivary ﬂow rate of
≥0.1 ml/min was found in the total ED group) is
refuted by the fact that there was no signiﬁcant diﬀer-
ence in the salivary secretion rate between subgroups of
ED and their matched controls. Nevertheless, anorexic
behavior and longer duration of ED seem to have a
signiﬁcant impact on salivary composition.
In the conditional regression analysis performed on
the total sample, the model identiﬁed ASAT and total
protein content to the best predictors in the set of vari-
ables analyzed for ED patients (OR = 3.5 and 2.5,
respectively), with sensitivity and speciﬁcity of 65% and
67%, respectively. In female subjects with EDs,
‘increased blood serum activities of ASAT was signiﬁ-
cantly correlated to lower BMI (27), had a high inci-
dence in critically-ill anorexic patients and was
considered to be a sign of multi-organ failure requiring
urgent caloric supplementation’ (28). Elevated levels of
serum transaminases are not a typical feature of starva-
tion alone, but this may be the case when occurring in
patients with EDs in combination with alcohol, drugs,
and/or medication abuse (29). Salivary ASAT in this
study, in addition to being a signiﬁcant predictor of
ED disease, also had a signiﬁcant, negative correlation
with BMI in the ED group, similar to that found in
blood serum (27). Consequently, it seems that salivary
levels of ASAT could be an important factor and this
deserves further investigation.
An elevated total protein level in unstimulated saliva
was another predictor for ED. In bulimic patients a
similar correlation has been reported (30), and it has
been speculated that the increase of salivary protein
concentrations in bulimic patients is caused by an
abnormal parotid sympathetic innervation resembling
that of stimulatory proteodyschylia (31). Nevertheless,
salivary and parotid gland aﬀection was common
among the patients with EDs in this study and it is
therefore not unlikely that the elevated concentrations
of salivary total protein mirror these conditions. In
bivariate analyses, ASAT and total protein concentra-
tions were also signiﬁcantly higher in subgroups of
patients with EDs with a longer duration of the disease
and in those who did not report vomiting/binge eating
behavior. If one agrees that these groups represent a
more severe presentation of ED disease, increased sali-
vary ASAT and protein levels may be an indication of
this increased severity.
In conclusion, elevated salivary concentrations of
ASAT and total protein may serve as indicators for
patients with EDs as well as of the severity of the
disease. Future studies are needed to corroborate these
preliminary ﬁndings.
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